The long anticipated Age Related Eye Disease Study part 2 (AREDS2) results were announced at the Association for Research in Vision and Ophthalmology (ARVO) in Seattle on May 5th 2013. This complex study began in 2006 and included 4203 participants and 82 clinics through the United States. It was designed to find out the best combination of vitamins, minerals and carotenoids to delay the progression of Age-related Macular Degeneration (AMD), currently a leading cause of sight loss in the developed world.

”Addition of lutein & zeaxanthin, DHA & EPA, or both to the AREDS formulation did not further reduce risk of progression to advanced AMD. However, because of the potential increased incidence of lung cancer in former smokers, lutein & zeaxanthin could be an appropriate substitute for beta-carotene in the AREDS formulation.”

These results offer clear advice to healthcare professionals as well as those diagnosed with AMD and their families as to which ingredients and importantly which exact doses to look for when choosing a supplement. There are many supplements on sale that claim to improve symptoms but they simply do not have enough of, or even the right ingredients in.